Cited by 49Retinal Development and DisordersRetinoids in leukemia and cellular processesRetinal Diseases and Treatments

The specific binding of retinoic acid to RPE65 and approaches to the treatment of macular degeneration

Open access
Gollapalli, Deviprasad R., Rando, Robert R.·2004·Proceedings of the National Academy of Sciences

Abstract

RPE65 is essential in the operation of the visual cycle and functions as a chaperone for all- trans -retinyl esters, the substrates for isomerization in the visual cycle. RPE65 stereospecifically binds all- trans -retinyl esters with a K D of 47 nM. It is shown here by using a quantitative fluorescence technique, that Accutane (13- cis -retinoic acid), a drug used in the treatment of acne but that causes night blindness, binds to RPE65 with a K D of 195 nM. All- trans -retinoic acid binds with a K D of 109 nM. The binding of the retinoic acids to RPE65 is competitive with all- trans -retinyl ester binding, and this competition inhibits visual cycle function. A retinoic acid analog that binds weakly to RPE65 is not inhibitory. These data suggest that RPE65 function is rate-limiting in visual cycle function. They also reveal the target through which the retinoic acids induce night blindness. Finally, certain forms of retinal and macular degeneration are caused by the accumulation of vitamin A-based retinotoxic products, called the retinyl pigment epithelium–lipofuscin. These retinotoxic products accumulate during the normal course of rhodopsin bleaching and regeneration after the operation of the visual cycle. Drugs such as Accutane may represent an important approach to reducing the accumulation of the retinotoxic lipofuscin by inhibiting visual cycle function. The identification of RPE65 as the visual cycle target for the retinoic acids makes it feasible to develop useful drugs to treat retinal and macular degeneration while avoiding the substantial side effects of the retinoic acids.

Integrity signals

Registry

Crossref · 10.1073/pnas.0401936101

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Isotretinoin reduces the accumulation of toxic byproducts of the visual cycle, such as A2E.

    “However, on the other hand, it reduces the accumulation of toxic byproducts of the visual cycle, such as N-retinyl-N-retinylidene ethanolamine (A2E) [16,17,18].”

    From The Role of Vitamin A in Retinal Diseases (2022) · cites this paper as [16]

  • In the RPE, isotretinoin inhibits two key visual cycle enzymes, RPE65 and 11-cis-retinol dehydrogenase.

    “In retina in the retinal pigment epithelium (RPE), isotretinoin inhibits two key visual cycle enzymes, RPE-specific 65 kDa protein (RPE65) [16] and 11-cis-retinol dehydrogenase [17,18] (Figure 1).”

    From The Role of Vitamin A in Retinal Diseases (2022) · cites this paper as [16]

  • Isotretinoin impairs the chromophore 11-cis-retinal and slows rhodopsin regeneration, which can cause night blindness.

    “This impairs chromophore, 11-cis-retinal, and slows rhodopsin (RHO) regeneration which can cause night blindness.”

    From The Role of Vitamin A in Retinal Diseases (2022) · cites this paper as [16]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Gollapalli, D. R., & Rando, R. R.
Affiliations
Harvard University (US)
Corresponding author
Rando, Robert R.
Venue
Proceedings of the National Academy of Sciences
Published
2004-06-24
Volume
101
Issue
27
Pages
10030-10035
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2066823591
Cited by
49
References
32
Citations by year
2025: 3 · 2022: 3 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 1 · 2016: 2 · 2015: 2 · 2013: 4 · 2012: 4
FWCI
2.02
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Eye Institute (R01EY004096, EY-04096, R37EY004096)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinal Development and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
Keywords
RPE65, retinoic acid binding, visual cycle, isotretinoin, night blindness, lipofuscin accumulation, retinal degeneration, macular degeneration, rhodopsin regeneration, competitive binding
MeSH terms
Retinyl Esters, Animals, Cattle, Diterpenes, Eye Proteins, Macular Degeneration, Proteins, Tretinoin, Vitamin A

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review